Magnesium Carbonate
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Magnesium Carbonate: Gastroduodenitis
One-Sentence Summary
Magnesium carbonate is an antacid originally used for acid-related conditions such as peptic ulcer disease, gastroesophageal reflux disease and dyspepsia. Support is weak: 0 clinical trials and 1 publication (an in vitro antacid quality study) are currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 0.9994 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, magnesium carbonate is an antacid that neutralizes gastric acid. Its use in acid-related disease is established, and mechanistically it may be applicable to active peptic ulcer disease through symptom relief.
Active peptic ulcer disease overlaps closely with the original peptic ulcer disease indication. The prediction is therefore better read as a confirmation of existing use than as a new repurposing opportunity. Acid neutralization can relieve symptoms, but the data compiled for this report contain no clinical outcome data on ulcer healing.
Other top-ranked predictions are mostly further acid-related conditions: gastric ulcer, duodenal ulcer, gastroduodenitis, gastrojejunal ulcer and duodenogastric reflux. Several have indirect support from in vitro or mucosal-protection studies. Predictions for peptic ulcer perforation, gastroparesis and duodenal obstruction have no supporting studies and weak mechanistic rationale, since these are surgical or motility problems that an antacid would not treat.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35720246 | 2022 | In vitro / product quality study | Medicine and Pharmacy Reports | Evaluated the acid-neutralizing capacity and other properties of antacids marketed in Morocco; no clinical outcome data |
For the other predicted conditions, only indirect evidence was found. Examples include an in vitro bile acid adsorption study of antacids (3440273), a human mucosal protection study against aspirin-induced injury using aluminium hydroxide–magnesium carbonate gel (3913424), and an artificial stomach-duodenum model of antacid efficacy (8763049). None studied patients with these ulcer conditions directly.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 175730 | Plegiocard Injection (Samarth Life Sciences Pvt Ltd) | Vial of 20 ml injection | Not stated |
| 43422 | Cardiplegin Injection (Troikaa Pharmaceuticals Ltd) | Vial of 20 ml injection | Not stated |
Both registered products are injectables. Neither is an oral antacid, so the registered forms do not match the route needed for acid-related indications.
Safety Considerations
- Contraindications (from knowledge-graph disease associations, not label text): liver failure, liver disease, hepatic coma and encephalopathy, kidney disease, nephrocalcinosis, hypercalcemia, hyperparathyroidism, porphyria, sarcoidosis, thrombocytopenia, neutropenia, agranulocytosis, anemia, diarrheal disease, obstructive sleep apnea, substance abuse/dependence, and anxiety and related disorders. These associations need confirmation against the product labelling.
- Drug Interactions: 197 interactions were recorded. The main ones are:
- Major: dolutegravir.
- Moderate: acalabrutinib, doxycycline, alendronic acid, risedronic acid, cholecalciferol, amphetamine, acetylsalicylic acid, atazanavir, atropine, azithromycin, baloxavir marboxil, benzphetamine.
- Minor: acebutolol, famotidine, ranitidine, alprazolam, atenolol, axitinib, benazepril.
Please refer to the package insert for key warnings and contraindications on the label.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication overlaps with an existing use, and no clinical trials exist. The only direct literature is an in vitro product-quality study, so evidence is at L5. The registered India products are injectables, which do not fit an oral antacid use.
To proceed, the following is needed:
- Package insert warnings and contraindications from the India licence holders (currently missing and blocking safety screening)
- Mechanism of action data from DrugBank
- Confirmation of whether any oral magnesium carbonate product is registered in India
- Clinical outcome data (such as ulcer healing) for the specific predicted conditions
- A clearer definition of what counts as a new indication versus the existing peptic ulcer use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.